Form 4: Bristol-Myers Squibb Director Acquires Deferred Share Units

Director Michael R. McMullen acquired 2,986.941 deferred share units of Bristol-Myers Squibb on July 1, 2024, convertible to common stock upon ceasing to be a director or at a specified future date.

Summary

• On July 1, 2024, Michael R. McMullen, a director of Bristol-Myers Squibb, acquired 2,986.941 deferred share units.
• These units are part of the 2024 annual Deferred Share Unit awards granted to the company's directors.
• Each deferred share unit will be converted into one share of common stock upon settlement.
• The deferred share units become settleable when McMullen ceases to be a director or at a future date he previously specified.
• The price of the deferred share units was $41.3.

Sentiment

Score: 7

Explanation: Director's acquisition of deferred share units is generally a positive sign, indicating confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of deferred share units by a director signals confidence in the company's future performance.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which occurs when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

Director share acquisitions are common in the pharmaceutical industry as part of executive compensation packages, aligning director interests with shareholder value.

Comparison to Industry Standards

• Deferred share unit grants are a typical component of director compensation packages in large pharmaceutical companies like Johnson & Johnson (JNJ) and Pfizer (PFE).
• These grants are often structured to vest over several years, encouraging long-term commitment and alignment with shareholder interests, similar to practices observed at Merck (MRK) and AbbVie (ABBV).

Stakeholder Impact

• The acquisition of deferred share units by a director can positively influence shareholder sentiment.

Key Dates